Clear Harbor Asset Management LLC Has $261,000 Stake in Arbutus Biopharma Co. (NASDAQ:ABUS)

Clear Harbor Asset Management LLC increased its position in shares of Arbutus Biopharma Co. (NASDAQ:ABUS) by 6.7% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 79,761 shares of the biopharmaceutical company’s stock after acquiring an additional 5,000 shares during the period. Clear Harbor Asset Management LLC’s holdings in Arbutus Biopharma were worth $261,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Helen Stephens Group LLC bought a new stake in shares of Arbutus Biopharma during the third quarter worth about $50,000. XTX Topco Ltd bought a new stake in Arbutus Biopharma during the 2nd quarter worth approximately $53,000. Ballentine Partners LLC acquired a new position in Arbutus Biopharma in the 4th quarter valued at approximately $102,000. China Universal Asset Management Co. Ltd. raised its stake in shares of Arbutus Biopharma by 63.8% during the third quarter. China Universal Asset Management Co. Ltd. now owns 36,309 shares of the biopharmaceutical company’s stock valued at $140,000 after acquiring an additional 14,138 shares during the last quarter. Finally, Intech Investment Management LLC bought a new position in shares of Arbutus Biopharma during the third quarter valued at $142,000. Institutional investors and hedge funds own 43.79% of the company’s stock.

Wall Street Analyst Weigh In

ABUS has been the subject of a number of recent research reports. HC Wainwright restated a “buy” rating and issued a $5.00 price objective on shares of Arbutus Biopharma in a report on Tuesday. JMP Securities increased their price target on Arbutus Biopharma to $5.00 and gave the company a “buy” rating in a research note on Wednesday, November 6th. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $5.00 price objective (up from $4.50) on shares of Arbutus Biopharma in a research note on Wednesday, November 20th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, Arbutus Biopharma currently has a consensus rating of “Moderate Buy” and an average price target of $5.50.

Arbutus Biopharma Trading Up 0.3 %

Shares of Arbutus Biopharma stock opened at $3.22 on Thursday. The business has a 50-day moving average price of $3.40 and a two-hundred day moving average price of $3.72. Arbutus Biopharma Co. has a 1-year low of $2.27 and a 1-year high of $4.72. The company has a market cap of $610.16 million, a P/E ratio of -7.49 and a beta of 1.78.

Arbutus Biopharma Company Profile

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.